Literature DB >> 25308556

Improvement of Cardiomyopathy After High-Fat Diet in Two Siblings with Glycogen Storage Disease Type III.

Alessandra Brambilla1, Savina Mannarino, Roberta Pretese, Serena Gasperini, Cinzia Galimberti, Rossella Parini.   

Abstract

Glycogenosis type III (GSD III) is an autosomal recessive disorder due to amylo-1,6-glucosidase deficiency. This disease causes limit dextrin storage in affected tissues: liver, skeletal muscles, and heart in GSD IIIa and only liver in GSD IIIb. Cardiomyopathy is quite frequent in GSD IIIa with variable severity and progression of manifestations. It is not clear if diet manipulation may interfere with cardiomyopathy's progression. Recent case reports showed improvement of cardiomyopathy following a ketogenic diet.Two siblings (girl and boy), 7- and 5-year-old, both affected with GSD IIIa, developed severe and rapidly worsening left ventricular hypertrophy in the first years of life, while treated with frequent diurnal and nocturnal hyperproteic meals followed by orally administered uncooked cornstarch. Subsequently they were treated with high-fat (60%) and high-protein (25%), low-carbohydrate (15%) diet. After 12 months exertion dyspnea disappeared in the girl and biochemical blood tests, cardiac enzymes, and congestive heart failure markers improved in both (CK 3439→324, 1304→581 U/L; NT-proBNP 2084→206, 782→135 pg/mL, respectively); ultrasound assessment in both patients showed a relevant reduction of the thickness of interventricular septum (30→16, 16→11 mm, respectively) and left ventricle posterior wall (18→7, 13→8 mm, respectively) and an improvement of the outflow obstruction. A diet rich in fats as well as proteins and poor in carbohydrates could be a beneficial therapeutic choice for GSD III with cardiomyopathy. Future research is needed to confirm the beneficial effect of this treatment and to design treatment strategies with the aim to provide alternative source of energy and prevent glycogen accumulation.

Entities:  

Year:  2014        PMID: 25308556      PMCID: PMC4241197          DOI: 10.1007/8904_2014_343

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  6 in total

1.  Cardiac Pathology in Glycogen Storage Disease Type III.

Authors:  S L Austin; A D Proia; M J Spencer-Manzon; J Butany; S B Wechsler; P S Kishnani
Journal:  JIMD Rep       Date:  2012-01-31

2.  Heart Failure Due to Severe Hypertrophic Cardiomyopathy Reversed by Low Calorie, High Protein Dietary Adjustments in a Glycogen Storage Disease Type IIIa Patient.

Authors:  Christiaan P Sentner; Kadir Caliskan; Wim B Vletter; G Peter A Smit
Journal:  JIMD Rep       Date:  2011-12-13

3.  Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D,L-3-hydroxybutyrate, ketogenic and high-protein diet.

Authors:  Vassili Valayannopoulos; Fanny Bajolle; Jean-Baptiste Arnoux; Sandrine Dubois; Nathalie Sannier; Christiane Baussan; François Petit; Philippe Labrune; Daniel Rabier; Chris Ottolenghi; Anne Vassault; Christine Broissand; Damien Bonnet; Pascale de Lonlay
Journal:  Pediatr Res       Date:  2011-12       Impact factor: 3.756

4.  Differential metabolic effects of saturated versus polyunsaturated fats in ketogenic diets.

Authors:  Brian S Fuehrlein; Michael S Rutenberg; Jared N Silver; Matthew W Warren; Douglas W Theriaque; Glen E Duncan; Peter W Stacpoole; Mark L Brantly
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

5.  Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet.

Authors:  A I Dagli; R T Zori; H McCune; T Ivsic; M K Maisenbacher; D A Weinstein
Journal:  J Inherit Metab Dis       Date:  2009-03-30       Impact factor: 4.982

6.  Glycogen storage disease type III diagnosis and management guidelines.

Authors:  Priya S Kishnani; Stephanie L Austin; Pamela Arn; Deeksha S Bali; Anne Boney; Laura E Case; Wendy K Chung; Dev M Desai; Areeg El-Gharbawy; Ronald Haller; G Peter A Smit; Alastair D Smith; Lisa D Hobson-Webb; Stephanie Burns Wechsler; David A Weinstein; Michael S Watson
Journal:  Genet Med       Date:  2010-07       Impact factor: 8.822

  6 in total
  14 in total

Review 1.  Ketogenic diets in patients with inherited metabolic disorders.

Authors:  S Scholl-Bürgi; A Höller; K Pichler; M Michel; E Haberlandt; D Karall
Journal:  J Inherit Metab Dis       Date:  2015-06-25       Impact factor: 4.982

Review 2.  Preclinical Development of New Therapy for Glycogen Storage Diseases.

Authors:  Baodong Sun; Elizabeth D Brooks; Dwight D Koeberl
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

3.  Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression.

Authors:  Patrice Vidal; Serena Pagliarani; Pasqualina Colella; Helena Costa Verdera; Louisa Jauze; Monika Gjorgjieva; Francesco Puzzo; Solenne Marmier; Fanny Collaud; Marcelo Simon Sola; Severine Charles; Sabrina Lucchiari; Laetitia van Wittenberghe; Alban Vignaud; Bernard Gjata; Isabelle Richard; Pascal Laforet; Edoardo Malfatti; Gilles Mithieux; Fabienne Rajas; Giacomo Pietro Comi; Giuseppe Ronzitti; Federico Mingozzi
Journal:  Mol Ther       Date:  2017-12-28       Impact factor: 11.454

Review 4.  Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions.

Authors:  Terry G J Derks; Margreet van Rijn
Journal:  J Inherit Metab Dis       Date:  2015-01-30       Impact factor: 4.982

5.  Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome.

Authors:  Christiaan P Sentner; Irene J Hoogeveen; David A Weinstein; René Santer; Elaine Murphy; Patrick J McKiernan; Ulrike Steuerwald; Nicholas J Beauchamp; Joanna Taybert; Pascal Laforêt; François M Petit; Aurélie Hubert; Philippe Labrune; G Peter A Smit; Terry G J Derks
Journal:  J Inherit Metab Dis       Date:  2016-04-22       Impact factor: 4.982

6.  Normalization of obstructive cardiomyopathy and improvement of hepatopathy on ketogenic diet in patient with glycogen storage disease (GSD) type IIIa.

Authors:  Tatiana Marusic; Mojca Zerjav Tansek; Andreja Sirca Campa; Ajda Mezek; Pavel Berden; Tadej Battelino; Urh Groselj
Journal:  Mol Genet Metab Rep       Date:  2020-07-16

7.  Modified Atkins ketogenic diet improves heart and skeletal muscle function in glycogen storage disease type III.

Authors:  Francesco Francini-Pesenti; Silvia Tresso; Nicola Vitturi
Journal:  Acta Myol       Date:  2019-03-01

8.  Variable clinical presentation of glycogen storage disease type IV: from severe hepatosplenomegaly to cardiac insufficiency. Some discrepancies in genetic and biochemical abnormalities.

Authors:  Edyta Szymańska; Sylwia Szymańska; Grażyna Truszkowska; Elżbieta Ciara; Maciej Pronicki; Yoon S Shin; Teodor Podskarbi; Alina Kępka; Mateusz Śpiewak; Rafał Płoski; Zofia T Bilińska; Dariusz Rokicki
Journal:  Arch Med Sci       Date:  2017-12-19       Impact factor: 3.318

9.  Glucose-free/high-protein diet improves hepatomegaly and exercise intolerance in glycogen storage disease type III mice.

Authors:  Serena Pagliarani; Sabrina Lucchiari; Gianna Ulzi; Michela Ripolone; Raffaella Violano; Francesco Fortunato; Andreina Bordoni; Stefania Corti; Maurizio Moggio; Nereo Bresolin; Giacomo P Comi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-08-01       Impact factor: 5.187

10.  Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment.

Authors:  Pascal Laforêt; Michio Inoue; Evelyne Goillot; Claire Lefeuvre; Umut Cagin; Nathalie Streichenberger; Sarah Leonard-Louis; Guy Brochier; Angeline Madelaine; Clemence Labasse; Carola Hedberg-Oldfors; Thomas Krag; Louisa Jauze; Julien Fabregue; Philippe Labrune; Jose Milisenda; Aleksandra Nadaj-Pakleza; Sabrina Sacconi; Federico Mingozzi; Giuseppe Ronzitti; François Petit; Benedikt Schoser; Anders Oldfors; John Vissing; Norma B Romero; Ichizo Nishino; Edoardo Malfatti
Journal:  Acta Neuropathol Commun       Date:  2019-10-28       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.